Siegel Lab

Research

Research in the Siegel laboratory uses bacterial and eukaryotic display technologies to generate novel antibody fragments to cell surface and soluble targets relevant to human health and disease. Types of antibodies include those derived from human, non-human primate, avian, rabbit, camelid, and dog immune repertoires. Current projects focus on the development of anti-blood cell scFv/drug fusion proteins for effective intravascular drug delivery, the design of solid tumor CAR-T cell receptors, and the isolation of canine antibody fragments from an ultra-large naïve bacteriophage display library for immunotherapy applications in dogs.